Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
Thomas Aparicio, Olivier Bouché, Julien Taı̈eb, et al.
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 133-138
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L. Bédard, David M. Hyman, Matthew S. Davids, et al.
The Lancet (2020) Vol. 395, Iss. 10229, pp. 1078-1088
Closed Access | Times Cited: 449
Larotrectinib: First Global Approval
Lesley J. Scott
Drugs (2019) Vol. 79, Iss. 2, pp. 201-206
Closed Access | Times Cited: 203
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
Anthony Dohan, B. Gallix, Boris Guiu, et al.
Gut (2019) Vol. 69, Iss. 3, pp. 531-539
Closed Access | Times Cited: 120
Older adults with cancer and their caregivers — current landscape and future directions for clinical care
Sindhuja Kadambi, Kah Poh Loh, Richard F. Dunne, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 742-755
Open Access | Times Cited: 98
Targeting Angiogenesis in Colorectal Carcinoma
Anthony Lopez, Kazuto Harada, Maria Vasilakopoulou, et al.
Drugs (2019) Vol. 79, Iss. 1, pp. 63-74
Closed Access | Times Cited: 58
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Stine Brændegaard Winther, Gábor Liposits, Halla Skúladóttir, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 5, pp. 376-388
Closed Access | Times Cited: 55
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
M. A. Gómez-España, Javier Gállego, E. González, et al.
Clinical & Translational Oncology (2018) Vol. 21, Iss. 1, pp. 46-54
Open Access | Times Cited: 55
The role of tumor angiogenesis as a therapeutic target in colorectal cancer
Francesca Battaglin, Alberto Puccini, Rossana Intini, et al.
Expert Review of Anticancer Therapy (2018) Vol. 18, Iss. 3, pp. 251-266
Open Access | Times Cited: 53
Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey
Florence Canouï‐Poitrine, Astrid Lièvre, F. Daydé, et al.
The Oncologist (2019) Vol. 24, Iss. 12, pp. e1351-e1359
Open Access | Times Cited: 51
Tumor-Agnostic Treatment for Cancer: When How is Better than Where
Daniele Lavacchi, Giandomenico Roviello, Alberto D’Angelo
Clinical Drug Investigation (2020) Vol. 40, Iss. 6, pp. 519-527
Closed Access | Times Cited: 39
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
Yu Song, Qianqian Mao, Manling Zhou, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
<p>Antitumor activity of larotrectinib in tumors harboring <em>NTRK&nbsp;</em>gene fusions: a short review on the current evidence</p>
Biagio Ricciuti, Carlo Genova, Lucio Crinó, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 3171-3179
Open Access | Times Cited: 42
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)
Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Journal of Clinical Oncology (2018) Vol. 37, Iss. 1, pp. 22-32
Closed Access | Times Cited: 41
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
Xin Wang, Zhigang Bai, Wei Deng, et al.
Investigational New Drugs (2025)
Closed Access
A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study
Gerardo Rosati, Maria Carmela Piccirillo, Guglielmo Nasti, et al.
Drugs & Aging (2025)
Closed Access
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
Thomas Aparicio, Michel Ducreux, Roger Faroux, et al.
European Journal of Cancer (2018) Vol. 98, pp. 1-9
Open Access | Times Cited: 37
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
Thomas Aparicio, Olivier Bouché, E. François, et al.
European Journal of Cancer (2018) Vol. 97, pp. 16-24
Closed Access | Times Cited: 36
Progress of research on molecular targeted therapies for colorectal cancer
Shilin Huang, Jiazhou Ye, Xing Gao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
Thomas Aparicio, Florence Canouï‐Poitrine, Philippe Caillet, et al.
Digestive and Liver Disease (2020) Vol. 52, Iss. 5, pp. 493-505
Open Access | Times Cited: 21
Development and validation of survival nomograms in colorectal cancer patients with synchronous liver metastases underwent simultaneous surgical treatment of primary and metastatic lesions.
Xiao Guo, Yang Liu, Lujia Liu, et al.
(2021) Vol. 11, Iss. 6, pp. 2654-2669
Closed Access | Times Cited: 18
Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?
Ishan Patel, Arthur Winer
Current Oncology Reports (2024) Vol. 26, Iss. 1, pp. 90-102
Closed Access | Times Cited: 2
Updates on the Management of Colorectal Cancer in Older Adults
C. O'Donnell, Joleen M. Hubbard, Zhaohui Jin
Cancers (2024) Vol. 16, Iss. 10, pp. 1820-1820
Open Access | Times Cited: 2
A novel long noncoding RNA OECC promotes colorectal cancer development and is negatively regulated by miR-143-3p
Fengting Huang, Chuangyu Wen, Yongxun Zhuansun, et al.
Biochemical and Biophysical Research Communications (2018) Vol. 503, Iss. 4, pp. 2949-2955
Open Access | Times Cited: 21
Update on the management of elderly patients with colorectal cancer
Gemma Soler-González, Javier Sastre-Valera, Antônio Brazil Viana, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 1, pp. 69-84
Open Access | Times Cited: 6
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD
Thomas Aparicio, Ariane Darut‐Jouve, F. Khemissa Akouz, et al.
Journal of Geriatric Oncology (2020) Vol. 11, Iss. 8, pp. 1255-1262
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top